The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic | ||
| dc.conicet.organizacion | Drexel University | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología "Dr. César Milstein" | |
| dc.conicet.organizacion | Drexel University | |
| dc.conicet.organizacion | Drexel University | |
| dc.contributor.author | Shah, Priyanka | |
| dc.contributor.author | Canziani, Gabriela Alicia | |
| dc.contributor.author | Carter, Erik P. | |
| dc.contributor.author | Chaiken, Irwin | |
| dc.date.issued | 2021-03 | |
| dc.description.abstract | As COVID-19 cases continue to rise, it is imperative to learn more about antibodies and T-cells produced against the causative virus, SARS-CoV-2, in order to guide the rapid development of therapies and vaccines. While much of the current antibody and vaccine research focuses on the receptor-binding domain of S1, a less-recognized opportunity is to harness the potential benefits of the more conserved S2 subunit. Similarities between the spike proteins of both SARS-CoV-2 and HIV-1 warrant exploring S2. Possible benefits of employing S2 in therapies and vaccines include the structural conservation of S2, extant cross-reactive neutralizing antibodies in populations (due to prior exposure to common cold coronaviruses), the steric neutralization potential of antibodies against S2, and the stronger memory B-cell and T-cell responses. More research is necessary on the effect of glycans on the accessibility and stability of S2, SARS-CoV-2 mutants that may affect infectivity, the neutralization potential of antibodies produced by memory B-cells, cross-reactive T-cell responses, antibody-dependent enhancement, and antigen competition. This perspective aims to highlight the evidence for the potential advantages of using S2 as a target of therapy or vaccine design. | es |
| dc.description.fil | Fil: Shah, Priyanka. Drexel University; Estados Unidos | |
| dc.description.fil | Fil: Canziani, Gabriela Alicia. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Parque Centenario. Instituto de Ciencia y Tecnología "Dr. César Milstein". Fundación Pablo Cassará. Instituto de Ciencia y Tecnología "Dr. César Milstein"; Argentina | |
| dc.description.fil | Fil: Carter, Erik P.. Drexel University; Estados Unidos | |
| dc.description.fil | Fil: Chaiken, Irwin. Drexel University; Estados Unidos | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Shah, Priyanka; Canziani, Gabriela Alicia; Carter, Erik P.; Chaiken, Irwin; The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic; Frontiers Media; Frontiers in Immunology; 12; 3-2021; 1-7 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 1664-3224 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/211394 | |
| dc.journal.pagination | 1-7 | es |
| dc.journal.pais | Suiza | es |
| dc.journal.title | Frontiers in Immunology | es |
| dc.journal.volume | 12 | es |
| dc.language.iso | eng | es |
| dc.publisher | Frontiers Media | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://www.frontiersin.org/articles/10.3389/fimmu.2021.637651/full | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.3389/fimmu.2021.637651 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | ANTIBODIES | es |
| dc.subject | CORONAVIRUS | es |
| dc.subject | COVID-19 | es |
| dc.subject | IMMUNITY | es |
| dc.subject | S2 SUBUNIT | es |
| dc.subject | SARS-COV-2 | es |
| dc.subject | SARS-COV-2 VACCINE | es |
| dc.subject | SPIKE PROTEIN | es |
| dc.subject.classification | Otras Biotecnologías de la Salud | es |
| dc.subject.classification | Biotecnología de la Salud | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.d4cecc9c-0d2c-40a4-8152-4e9120c36890_B.pdf
- Tamaño:
- 367.58 KB
- Formato:
- Adobe Portable Document Format